LAROTAXEL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C45H53NO14
Molecular Weight	831.9006
Optical Activity	UNSPECIFIED
Defined Stereocenters	11 / 11
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@H]4[C@]5(C[C@H]5C[C@H]6OC[C@@]46OC(C)=O)C1=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C7=CC=CC=C7

InChI

InChIKey=DXOJIXGRFSHVKA-BZVZGCBYSA-N

InChI=1S/C45H53NO14/c1-23-29(57-39(52)33(49)32(26-15-11-9-12-16-26)46-40(53)60-41(4,5)6)21-45(54)37(58-38(51)27-17-13-10-14-18-27)35-43(36(50)34(56-24(2)47)31(23)42(45,7)8)20-28(43)19-30-44(35,22-55-30)59-25(3)48/h9-18,28-30,32-35,37,49,54H,19-22H2,1-8H3,(H,46,53)/t28-,29+,30-,32+,33-,34-,35+,37+,43-,44+,45-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C45H53NO14
Molecular Weight	831.9006
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 11
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/mesh/67531079 | https://www.cancer.gov/publications/dictionaries/cancer-drug/def/larotaxel | https://www.ncbi.nlm.nih.gov/pubmed/11472265

LAROTAXEL is a taxoid with potential antineoplastic activity. It prevents microtubule depolymerization, thereby inhibiting cell proliferation. It displays a broad spectrum of antitumor activity in vitro and in vivo, including activity against P-glycoprotein expressing tumors. LAROTAXEL was in phase III clinical trials for the treatment of breast cancer, pancreatic cancer, and bladder cancer. However, its development was discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tubulin 69 Target ID: CHEMBL2095182 Sources: Weber, G.F. (2015) Molecular Therapies of Cancer, page 117, retrieved from: https://books.google.ru/books?id=dhs_CgAAQBAJ	Activator 1430

PubMed

Title	Date	PubMed
Preclinical evaluation of new taxoids.	2001 Sep	11472265
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.	2008 Jul	18381372
Larotaxel: broadening the road with new taxanes.	2009 Aug	19604119

Patents

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:45:03 GMT 2023` Edited by `admin` on `Sat Dec 16 16:45:03 GMT 2023`
Record UNII	TWQ8K8A81Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LAROTAXEL

Official Name

English

1-HYDROXY-9-OXO-5.BETA.,20-EPOXY-7.BETA.,19-CYCLOTAX-11-ENE-2.ALPHA.,4,10.BETA.,13.ALPHA.-TETRAYL 4,10-DIACETATE 2-BENZOATE 13-((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOATE)

Common Name

English

larotaxel [INN]

Common Name

English

XRP-9881

Code

English

XRP9881

Code

English

Larotaxel [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1490